home / stock / scyx / scyx short
Short Information | SCYNEXIS Inc. (NASDAQ:SCYX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,568,939 |
Total Actual Volume | 5,955,492 |
Short Trends | |
---|---|
Cover Days | 16 |
Short Days | 0 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 78,447 |
Average Short Percentage | 25.89% |
Is there a SCYX Short Squeeze or Breakout about to happen?
See the SCYX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-17-2024 | $2.55 | $2.77 | $2.9 | $2.4601 | 901,870 | 245,550 | 27.23% |
05-16-2024 | $2.29 | $2.41 | $2.68 | $2.21 | 1,234,622 | 348,200 | 28.2% |
05-15-2024 | $1.99 | $2.26 | $2.27 | $1.99 | 608,676 | 83,664 | 13.75% |
05-14-2024 | $2.03 | $1.97 | $2.05 | $1.84 | 281,964 | 56,577 | 20.07% |
05-13-2024 | $1.94 | $2.04 | $2.17 | $1.93 | 370,279 | 93,654 | 25.29% |
05-10-2024 | $1.9 | $1.94 | $1.98 | $1.85 | 366,457 | 119,807 | 32.69% |
05-09-2024 | $1.98 | $1.88 | $1.98 | $1.8227 | 140,242 | 48,788 | 34.79% |
05-08-2024 | $1.84 | $1.84 | $1.86 | $1.8 | 94,844 | 11,111 | 11.72% |
05-07-2024 | $1.73 | $1.845 | $1.92 | $1.725 | 219,530 | 64,686 | 29.47% |
05-06-2024 | $1.79 | $1.73 | $1.79 | $1.72 | 113,510 | 40,740 | 35.89% |
05-03-2024 | $1.8 | $1.77 | $1.9 | $1.7 | 173,113 | 27,260 | 15.75% |
05-02-2024 | $1.74 | $1.78 | $1.79 | $1.7001 | 120,933 | 45,978 | 38.02% |
05-01-2024 | $1.66 | $1.72 | $1.74 | $1.61 | 63,810 | 17,724 | 27.78% |
04-30-2024 | $1.79 | $1.69 | $1.8 | $1.68 | 236,966 | 64,076 | 27.04% |
04-29-2024 | $1.56 | $1.82 | $1.95 | $1.5531 | 438,724 | 162,411 | 37.02% |
04-26-2024 | $1.45 | $1.54 | $1.59 | $1.45 | 157,721 | 32,025 | 20.3% |
04-25-2024 | $1.48 | $1.47 | $1.4899 | $1.42 | 120,233 | 19,477 | 16.2% |
04-24-2024 | $1.58 | $1.5 | $1.5945 | $1.48 | 87,658 | 20,303 | 23.16% |
04-23-2024 | $1.48 | $1.55 | $1.6058 | $1.48 | 151,685 | 53,880 | 35.52% |
04-22-2024 | $1.45 | $1.44 | $1.48 | $1.44 | 72,655 | 13,028 | 17.93% |
News, Short Squeeze, Breakout and More Instantly...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...